Prof. RANA KARABUDAK

Personal Information

Office Phone: +90 312 305 1809
Fax Phone: +90 312 305 1983
Email: rkbudak@hacettepe.edu.tr
Web: http://ranakarabudak.com/iletisim.php
Address: Hacettepe Üniversitesi Tıp Fakültesi Nöroloji Anabilim Dalı, Sıhhıye, Ankara, 06100

International Researcher IDs
ORCID: 0000-0003-4272-1482
Yoksis Researcher ID: 170576

Education Information

Expertise In Medicine, Hacettepe University, Tıp Fakültesi, Nöroloji Anabilim Dalı, Turkey 1984 - 1990
Undergraduate, Ankara University, Tıp Fakültesi, Turkey 1975 - 1981

Foreign Languages

English, C1 Advanced

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Neurology

Published journal articles indexed by SCI, SSCI, and AHCI

I. **Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study**
Spelman T., Simoneau G., Hyde R., Kuhelj R., Alroughani R., Ozakbas S., Karabudak R., Yamout B. I., Khoury S. J., Terzi M., et al.
Neurology, vol.102, no.7, 2024 (SCI-Expanded)

II. **Navigating the discontinuation of multiple sclerosis first line treatments: A paradigm shift in patient care**
Ozen N. P. A., Dursun E. G., Tuncer A., KARABUDAK R.
Multiple Sclerosis and Related Disorders, vol.84, 2024 (SCI-Expanded)

III. **Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry**
Signori A., Ponzano M., Kalincik T., Ozakbas S., Horakova D., Havrdova E. K., Alroughani R., Patti F., Kuhle J., Izquierdo G., et al.
Journal of Neurology, Neurosurgery and Psychiatry, 2024 (SCI-Expanded)

IV. **Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies**
Li Y., Saul A., Taylor B., Ponsonby A., Simpson-Yap S., Blizzard L., Broadley S., Lechner-Scott J., KARABUDAK R., Patti

F., et al.
Journal of neurology, vol.271, no.1, pp.472-485, 2024 (SCI-Expanded)

V. **Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial**
Diouf I., Malpas C. B., Sharmin S., Roos I., Horakova D., Kubala Havrdova E., Patti F., Shaygannejad V., Ozakbas S., Eichau S., et al.
Journal of neurology, neurosurgery, and psychiatry, vol.94, no.12, pp.1004-1011, 2023 (SCI-Expanded)

VI. **The risk of secondary progressive multiple sclerosis is geographically determined but modifiable**
Sharmin S., Roos I., Simpson-Yap S., Malpas C., Sánchez M. M., Ozakbas S., Horakova D., Havrdova E. K., Patti F., Alroughani R., et al.
Brain : a journal of neurology, vol.146, no.11, pp.4633-4644, 2023 (SCI-Expanded)

VII. **Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment**
Sen S., Tuncer A., Terzi M., BÜNÜL S. D., Ozen-Acar P., Altunrende B., ÖZAKBAŞ S., Tutuncu M., UYGUNOĞLU U., Akman-Demir G., et al.
Multiple Sclerosis and Related Disorders, vol.79, 2023 (SCI-Expanded)

VIII. **Reliability and validity of the glittre activities of daily living test in fully ambulatory multiple sclerosis patients**
Kaya G., KÖSE N., SALCI Y., ARMUTLU K., Karakaya J., Tuncer A., KARABUDAK R.
Irish Journal of Medical Science, vol.192, no.5, pp.2379-2386, 2023 (SCI-Expanded)

IX. **Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial**
Lebrun-Frénay C., SİVA A., Sormani M. P., Landes-Chateau C., Mondot L., Bovis F., Vermersch P., Papeix C., Thouvenot E., Labauge P., et al.
JAMA neurology, vol.80, no.10, pp.1080-1088, 2023 (SCI-Expanded)

X. **Disability accrual in primary and secondary progressive multiple sclerosis**
Harding-Forrester S., Roos I., Nguyen A., Malpas C. B., Diouf I., Moradi N., Sharmin S., Izquierdo G., Eichau S., Patti F., et al.
Journal of Neurology, Neurosurgery and Psychiatry, vol.94, no.9, pp.707-717, 2023 (SCI-Expanded)

XI. **Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center**
BAHAR Y., YILDIZ E., Bahar A. R., KARABUDAK R.
Turkish Journal of Medical Sciences, vol.53, no.4, pp.962-969, 2023 (SCI-Expanded)

XII. **Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study**
Cohen M., Thomel-Rocchi O., SİVA A., Okuda D. T., KARABUDAK R., EFENDİ H., Terzi M., Carra-Dalliere C., Durand-Dubief F., Thouvenot E., et al.
Multiple Sclerosis Journal, vol.29, no.9, pp.1099-1106, 2023 (SCI-Expanded)

XIII. **Sars-CoV2 infection in pregnant women with multiple sclerosis**
Aprea M. G., Schiavetti I., Portaccio E., Ballerini C., Battaglia M. A., Bergamaschi R., Brichetto G., Bunul S. D., Calabrese M., Capobianco M., et al.
Multiple Sclerosis Journal, vol.29, no.9, pp.1090-1098, 2023 (SCI-Expanded)

XIV. **Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis**
Kalincik T., Sharmin S., Roos I., Freedman M. S., Atkins H., Burman J., Massey J., Sutton I., Withers B., MacDonell R., et al.
JAMA Neurology, vol.80, no.7, pp.702-713, 2023 (SCI-Expanded)

XV. **mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?**
Tütüncü M., Demir S., Arslan G., Dinç Ö., Şen S., GÜNDÜZ T., Uzunköprü C., Gümüş H., Tütüncü M., Akçin R., et al.
Multiple Sclerosis and Related Disorders, vol.75, 2023 (SCI-Expanded)

XVI. **Early non-disabling relapses are important predictors of disability accumulation in people with**

relapsing-remitting multiple sclerosis
Daruwalla C., Shaygannejad V., ÖZAKBAŞ S., Havrdova E. K., Horakova D., Alroughani R., BOZ C., Patti F., Onofrj M., Lugaresi A., et al.
Multiple sclerosis (Houndmills, Basingstoke, England), vol.29, no.7, pp.875-883, 2023 (SCI-Expanded)

XVII. **The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis**
BOZ C., ÖZAKBAŞ S., Terzi M., KARABUDAK R., Sevim S., Turkoglu R., Soysal A., Balcı B. P., EFENDİ H., TURAN Ö. F., et al.
Neurological Sciences, vol.44, no.6, pp.2121-2129, 2023 (SCI-Expanded)

XVIII. **Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis**
Diouf I., Malpas C. B., Sharmin S., Roos I., Horakova D., Havrdova E. K., Patti F., Shaygannejad V., ÖZAKBAŞ S., Izquierdo G., et al.
European Journal of Neurology, vol.30, no.4, pp.1014-1024, 2023 (SCI-Expanded)

XIX. **External validation of a clinical prediction model in multiple sclerosis**
Moradi N., Sharmin S., Malpas C. B., Shaygannejad V., Terzi M., BOZ C., Yamout B., Khoury S. J., Turkoglu R., KARABUDAK R., et al.
Multiple Sclerosis Journal, vol.29, no.2, pp.261-269, 2023 (SCI-Expanded)

XX. **Perivascular PDGFRB+ cells accompany lesion formation and clinical evolution differentially in two different EAE models**
Şekerdağ-Kılıç E., Ulusoy C., Atak D., Özkan E., Gökyüzü A. B., Seyaj S., Deniz G., Uçar E. A., Budan A. S., Zeybel M., et al.
Multiple Sclerosis and Related Disorders, vol.69, 2023 (SCI-Expanded)

XXI. **Comparative effectiveness in multiple sclerosis: A methodological comparison**
Roos I., Diouf I., Sharmin S., Horakova D., Havrdova E. K., Patti F., Shaygannejad V., ÖZAKBAŞ S., Izquierdo G., Eichau S., et al.
Multiple Sclerosis Journal, vol.29, 2023 (SCI-Expanded)

XXII. **The acute effect of cervical mobilization on balance in patients with multiple sclerosis: a single-blind, randomized, controlled trial**
KARANFİL E., SALCI Y., FİL BALKAN A., Tuncer A., KARABUDAK R.
Neurological Research, vol.46, no.1, pp.65-71, 2023 (SCI-Expanded)

XXIII. **Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)**
Tuncer A., Kürtüncü M., Terzi M., UYGUNOĞLU U., Göncüoğlu C., Yüceyar A. N., Ekmekçi Ö., Türkoğlu R., Soysal A., Köseoğlu M., et al.
Turkish Journal of Medical Sciences, vol.53, no.1, pp.323-332, 2023 (SCI-Expanded)

XXIV. **The Effect of Smoking on Inactivated and mRNA Vaccine Responses Applied to Prevent COVİD-19 in Multiple Sclerosis**
Şen S., Arslan G., Tütüncü M., Demir S., Dinç Ö., GÜNDÜZ T., Uzunköprü C., Gümüş H., Tütüncü M., Akçin R., et al.
Noropsikiyatri Arsivi, vol.60, no.3, pp.252-256, 2023 (SCI-Expanded)

XXV. **Defining the experiences of adolescent patients with multiple sclerosis in transition from pediatric care to adult care**
Yilmaz D. Y., YARDIMCI F., Erdemir F., KARABUDAK R.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.68, 2022 (SCI-Expanded)

XXVI. **Combined Central and Peripheral Demyelination in a Case With Sjogren Syndrome**
SÖKMEN O., GÖÇMEN R., NURLU G., KARABUDAK R.
NEUROLOGIST, vol.27, no.6, pp.354-356, 2022 (SCI-Expanded)

XXVII. **Updated Results of the COVID-19 in MS Global Data Sharing Initiative Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity**
Simpson-Yap S., Pirmani A., Kalincik T., De Brouwer E., Geys L., Parciak T., Helme A., Rijke N., Hillert J. A., Moreau Y., et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, vol.9, no.6, 2022 (SCI-Expanded)

XXVIII. **Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in**

multiple sclerosis
Zhu C., Zhou Z., Roos I., Merlo D., Kalincik T., ÖZAKBAŞ S., Skibina O., Kuhle J., Hodgkinson S., Boz C., et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, vol.93, pp.1330-1337, 2022 (SCI-Expanded)

XXIX. **Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-beta**
Simpson-Yap S., Pirmani A., De Brouwer E., Peeters L. M., Geys L., Parciak T., Helme A., Hillert J., Moreau Y., Edan G., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.66, 2022 (SCI-Expanded)

XXX. **A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis**
Ponzano M., Schiavetti I., Bovis F., Landi D., Carmisciano L., De Rossi N., Cordioli C., Moiola L., Radaelli M., Immovilli P., et al.
Multiple Sclerosis and Related Disorders, vol.63, 2022 (SCI-Expanded)

XXXI. **Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis An International Registry Study**
Vitkova M., Diouf I., Malpas C., Horakova D., Havrdova E. K., Patti F., ÖZAKBAŞ S., Izquierdo G., Eichau S., Shaygannejad V., et al.
NEUROLOGY, vol.98, no.24, 2022 (SCI-Expanded)

XXXII. **Hidden Markov Model and multifractal method-based predictive quantization complexity models vis-a-vis the differential prognosis and differentiation of Multiple Sclerosis' subgroups**
Karaca Y., BALEANU D., KARABUDAK R.
KNOWLEDGE-BASED SYSTEMS, vol.246, 2022 (SCI-Expanded)

XXXIII. **Prediction of multiple sclerosis outcomes when switching to ocrelizumab**
Zhong M., van der Walt A., Stankovich J., Kalincik T., Buzzard K., Skibina O., BOZ C., Hodgkinson S., Slee M., Lechner-Scott J., et al.
MULTIPLE SCLEROSIS JOURNAL, vol.28, no.6, pp.958-969, 2022 (SCI-Expanded)

XXXIV. **Post-COVID-19 longitudinally extensive transverse myelitis: is it a new entity?**
ARSLAN D., Acar-Ozen P., GÖÇMEN R., ELİBOL B., KARABUDAK R., Tuncer A.
NEUROLOGICAL SCIENCES, vol.43, no.3, pp.1569-1573, 2022 (SCI-Expanded)

XXXV. **The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?**
Sen S., Tuncer A., ÖZAKBAŞ S., Uzunkopru C., Baba C., Demir S., BECKMANN Y., GÜMÜŞ H., Arslan G., Kilic A. K., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.58, 2022 (SCI-Expanded)

XXXVI. **Coexistence of restless legs syndrome and multiple sclerosis aggravates anxiety and depression**
Sevim S., DEMİRKIRAN D. M., TERZİ M., YÜCEYAR A. N., Tasdelen B., İDİMAN E., Kurtuncu M., BOZ C., TUNCEL D., KARABUDAK R., et al.
ARQUIVOS DE NEURO-PSIQUIATRIA, vol.80, pp.168-172, 2022 (SCI-Expanded)

XXXVII. **Tumefactive demyelinating lesion in patient with neuromyelitis optica spectrum disorder**
Topkan T. A., SÖKMEN O., Kocer B., KARABUDAK R., UYAR GÖÇÜN F. P.
NEUROLOGIA I NEUROCHIRURGIA POLSKA, vol.56, no.3, pp.285-287, 2022 (SCI-Expanded)

XXXVIII. **Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective**
Arslan B., Arslan G. A., Tuncer A., KARABUDAK R., SEPİCİ DİNÇEL A.
BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, vol.22, no.5, pp.699-706, 2022 (SCI-Expanded)

XXXIX. **Factors associated with fingolimod rebound: A single center real-life experience**
Goncuoglu C., Tuncer A., Bayraktar-Ekincioglu A., Cagan C. A., Acar-Ozen P., ÇAKAN M., KARABULUT E., KARABUDAK R.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.56, 2021 (SCI-Expanded)

XL. **Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018**
Moradi N., Sharmin S., Malpas C., ÖZAKBAŞ S., Shaygannejad V., TERZİ M., BOZ C., Yamout B., Turkoglu R., KARABUDAK R., et al.
CNS DRUGS, vol.35, no.10, pp.1097-1106, 2021 (SCI-Expanded)

XLI. **The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies**

Andersen J. B., Sharmin S., Lefort M., Koch-Henriksen N., Sellebjerg F., Sorensen P. S., Christensen C. C. H., Rasmussen P., Jensen M. B., Frederiksen J. L., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.53, 2021 (SCI-Expanded)

XLII. **Evaluation of Thiol Homeostasis in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders**
Arslan B., Arslan G. A., Tuncer A., KARABUDAK R., SEPİCİ DİNÇEL A.
FRONTIERS IN NEUROLOGY, vol.12, 2021 (SCI-Expanded)

XLIII. **An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-beta 1 and fingolimod therapy**
Acar N. P., Tuncer A., Ozkazanc D., Ozbay F. G., KARAOSMANOĞLU B., Goksen S., Sayat G., Taskiran E. Z., ESENDAĞLI G., KARABUDAK R.
JOURNAL OF NEUROIMMUNOLOGY, vol.347, 2020 (SCI-Expanded)

XLIV. **'Is RLS a harbinger and consequence of MS?: Striking results of the 'RELOMS-T' study'**
Sevim S., Demirkiran M., TERZİ M., YÜCEYAR A. N., Tasdelen B., İDİMAN E., Kurtuncu M., BOZ C., TUNCEL D., KARABUDAK R., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.42, 2020 (SCI-Expanded)

XLV. **Early clinical markers of aggressive multiple sclerosis**
Malpas C. B., Manouchehrinia A., Sharmin S., Roos I., Horakova D., Havrdova E. K., Trojano M., Izquierdo G., Eichau S., Bergamaschi R., et al.
BRAIN, vol.143, pp.1400-1413, 2020 (SCI-Expanded)

XLVI. **Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder**
Kunchok A., Malpas C., Nytrova P., Havrdova E. K., Alroughani R., TERZİ M., Yamout B., Hor J. Y., KARABUDAK R., BOZ C., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.38, 2020 (SCI-Expanded)

XLVII. **Predictors of progression in primary progressive multiple sclerosis in a large Turkish cohort**
Vural A., Derle E., Sayat-Gurel G., KARABUDAK R., Tuncer A.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.38, 2020 (SCI-Expanded)

XLVIII. **Retinal degeneration is associated with brain volume reduction and prognosis in radiologically isolated syndrome**
Vural A., Okar S., Kurne A., Sayat-Gurel G., Acar N. P., KARABULUT E., Oguz K. K., KADAYIFÇILAR S., KARABUDAK R.
MULTIPLE SCLEROSIS JOURNAL, vol.26, no.1, pp.38-47, 2020 (SCI-Expanded)

XLIX. **Differences Between General Neurologists and Multiple Sclerosis Specialists in the Management of Multiple Sclerosis Patients: A National Survey**
Kurtuncu M., Tuncer A., Uygunoglu U., Caliskan Z., Kokenli Paksoy A., EFENDİ H., Sagduyu Kocaman A., Ozcan C., TERZİ M., TURAN Ö. F., et al.
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.56, no.4, pp.269-272, 2019 (SCI-Expanded)

L. **Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis**
BOZ C., TERZİ M., Ozer B., Turkoglu R., KARABUDAK R., EFENDİ H., Soysal A., Sevim S., Altintas A., Kurne A., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.36, 2019 (SCI-Expanded)

LI. **Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis**
Kalincik T., Havrdova E. K., Horakova D., Izquierdo G., Prat A., Girard M., Duquette P., Grammond P., Onofrj M., Lugaresi A., et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, vol.90, no.4, pp.458-468, 2019 (SCI-Expanded)

LII. **Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course**
Kaymakamzade B., Kilic A. K., Tuncer Kurne A., KARABUDAK R.
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.56, no.1, pp.23-26, 2019 (SCI-Expanded)

LIII. **Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing-remitting multiple sclerosis patients treated with fingolimod?**
Kocyigit D., YALÇIN M. U., Gurses K. M., Tokgozoglu L., KARABUDAK R.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.27, pp.276-280, 2019 (SCI-Expanded)

LIV. **Cerebrospinal fluid oligoclonal banding patterns and intrathecal immunoglobulin synthesis: Data comparison from a wide patient group**
PINAR A., Kurne A. T., LAY İ., Acar N. P., KARAHAN S., KARABUDAK R., Akbiyik F.
NEUROLOGICAL SCIENCES AND NEUROPHYSIOLOGY, vol.35, no.1, pp.21-28, 2018 (SCI-Expanded)

LV. **Validity and reliability of the International Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of Ataxia (SARA) in multiple sclerosis patients with ataxia**
SALCI Y., FİL BALKAN A., KEKLİCEK H., ÇETİN B., ARMUTLU K., Dolgun A., Tuncer A., KARABUDAK R.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.18, pp.135-140, 2017 (SCI-Expanded)

LVI. **Effects of different exercise modalities on ataxia in multiple sclerosis patients: a randomized controlled study**
SALCI Y., FİL BALKAN A., ARMUTLU K., Yildiz F. G., Kurne A., AKSOY S., NURLU G., KARABUDAK R.
DISABILITY AND REHABILITATION, vol.39, no.26, pp.2626-2632, 2017 (SCI-Expanded)

LVII. **Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet?**
Dahdaleh M., Alroughani R., Aljumah M., AlTahan A., Alsharoqi I., Bohlega S. A., Daif A., Deleu D., Inshasi J., KARABUDAK R., et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE, vol.127, no.10, pp.944-951, 2017 (SCI-Expanded)

LVIII. **The association of cognitive impairment with gray matter atrophy and cortical lesion load in clinically isolated syndrome**
Diker S., Has A. C., Kurne A., GÖÇMEN R., Oguz K. K., KARABUDAK R.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.10, pp.14-21, 2016 (SCI-Expanded)

LIX. **Unfavorable outcome of pediatric onset multiple sclerosis: Follow-up in the pediatric and adult neurology departments of one referral center, in Turkey**
Derle E., Kurne A. T., KONUŞKAN B., KARABUDAK R., Anlar B.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.9, pp.1-4, 2016 (SCI-Expanded)

LX. **Acute Disseminated Encephalomyelitis after Oral Therapy with Herbal Extracts: A Case Report**
Kaymakamzade B., KARABUDAK R., Kurne A. T., NURLU G.
BALKAN MEDICAL JOURNAL, vol.33, no.3, pp.366-369, 2016 (SCI-Expanded)

LXI. **Assessment of the effect of cigarette smoking on regional brain volumes and lesion load in patients with clinically isolated syndrome**
Durhan G., Diker S., Has A. C., Karakaya J., Kurne A. T., KARABUDAK R., Oguz K. K.
INTERNATIONAL JOURNAL OF NEUROSCIENCE, vol.126, no.9, pp.805-811, 2016 (SCI-Expanded)

LXII. **Fulminant Central Plus Peripheral Nervous System Demyelination without Antibodies to Neurofascin**
Vural A., GÖÇMEN R., KURNE A. T., OGUZ K. K., TEMUÇİN Ç. M., TAN E., KARABUDAK R., MEINL E., OZDAMAR S. E.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, vol.43, no.1, pp.149-156, 2016 (SCI-Expanded)

LXIII. **Rituximab in Turkish neuromyelitis optica patients with limited response to other immunosuppressants**
ERDENER Ş. E., KURNE A. T., DIKER S., KARABUDAK R.
JOURNAL OF THE NEUROLOGICAL SCIENCES, vol.359, pp.106-107, 2015 (SCI-Expanded)

LXIV. **Magnetic Resonance Imaging as a Major Milestone in Multiple Sclerosis Diagnosis and Treatment**
KARABUDAK R.
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.52, 2015 (SCI-Expanded)

LXV. **Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort Demographic, Clinical, and Laboratory Features**
Altintas A., KARABUDAK R., Balci B. P., TERZİ M., Soysal A., Saip S., Kurne A. T., Uygunoglu U., Nalbantoglu M., Celik G. G., et al.
NEUROLOGIST, vol.20, no.4, pp.61-66, 2015 (SCI-Expanded)

LXVI. **Functional clinical outcomes in multiple sclerosis: Current status and future prospects**
KARABUDAK R., Dahdaleh M., Aljumah M., Alroughani R., Alsharoqi I. A., AlTahan A. M., Bohlega S. A., Daif A., Deleu D., Amous A., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.4, no.3, pp.192-201, 2015 (SCI-Expanded)

LXVII. **Promotion of experimental autoimmune encephalomyelitis upon neutrophil granulocytes'**

stimulation with formyl-methionyl-leucyl-phenylalanine (fMLP) peptide
KILIÇ A., ESENDAĞLI G., SAYAT G., TALİM B., KARABUDAK R., KURNE A.
AUTOIMMUNITY, vol.48, no.6, pp.423-428, 2015 (SCI-Expanded)

LXVIII. **Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Turkey**
KARABUDAK R., Karampampa K., Caliskan Z.
JOURNAL OF MEDICAL ECONOMICS, vol.18, no.1, pp.69-75, 2015 (SCI-Expanded)

LXIX. **The Course of Myasthenia Gravis with Systemic Lupus Erythematosus**
Bekircan-Kurt C. E., Kurne A. T., Erdem-Ozdamar S., Kalyoncu U., Karabudak R., Tan E.
EUROPEAN NEUROLOGY, vol.72, pp.326-329, 2014 (SCI-Expanded)

LXX. **Mass Lesions in the Brain: Tumor or Multiple Sclerosis? Clinical and Imaging Characteristics and Course from a Single Reference Center**
Kilic A. K., Tuncer Kurne A., Karli Oguz K., Soylemezoglu F., KARABUDAK R.
TURKISH NEUROSURGERY, vol.23, no.6, pp.728-735, 2013 (SCI-Expanded)

LXXI. **Evaluation of Th17-related cytokines and receptors in multiple sclerosis patients under interferon beta-1 therapy**
ESENDAĞLI G., Kurne A. T., Sayat G., Kilic A. K., Guc D., KARABUDAK R.
JOURNAL OF NEUROIMMUNOLOGY, vol.255, pp.81-84, 2013 (SCI-Expanded)

LXXII. **Myasthenia Gravis; Single Entity, Variable Clinical Features: Ten Years of Clinical Experience in a Tertiary Care Center Ten Years Clinical Experience of a Tertiary Care Center**
BEKIRCAN-KURT C. E., KURNE A., ERDEM ÖZDAMAR S., KARABUDAK R., KANSU T., TAN E.
JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH, vol.30, no.1, pp.135-143, 2013 (SCI-Expanded)

LXXIII. **Comparing routine neurorehabilitation program with trunk exercises based on Bobath concept in multiple sclerosis: Pilot study**
Keser I., Kirdi N., Meric A., Kurne A. T., Karabudak R.
JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT, vol.50, no.1, pp.133-140, 2013 (SCI-Expanded)

LXXIV. **Lack of association of the CD14/C-159T polymorphism with susceptibility and progression parameters in Turkish multiple sclerosis patients**
Kurne A., Sayat G., Aydin O. F., Turgutoglu N., Terzi M., Sackesen C., KARABULUT E., KARABUDAK R.
JOURNAL OF NEUROIMMUNOLOGY, vol.250, pp.83-86, 2012 (SCI-Expanded)

LXXV. **Involvement of Autonomic Nervous System and its Relationship With Cranial and Cervical Spinal MRI Findings In Patients With Multiple Sclerosis**
Ciftci O., KESER İ., Kurne A., Bosnak Guclu M., Karli Oguz K., Soylu R., ARMUTLU K., AYTEMİR K., Tokgozoglu L., KARABUDAK R.
JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH, vol.29, no.2, pp.181-191, 2012 (SCI-Expanded)

LXXVI. **Improvement of muscle strength and fatigue with high voltage pulsed galvanic stimulation in multiple sclerosis patients - a non-randomized controlled trial**
Korkmaz N. C., Kirdi N., TEMUÇİN Ç. M., ARMUTLU K., Yakut Y., KARABUDAK R.
JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, vol.61, no.8, pp.736-743, 2011 (SCI-Expanded)

LXXVII. **Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: evaluation of expression under immunomodulatory therapy**
Kurne A., Guc D., CANPINAR H., Aydin O. F., Sayat G., Yorubulut M., ESENDAĞLI G., KARABUDAK R.
ACTA NEUROLOGICA SCANDINAVICA, vol.123, no.1, pp.8-12, 2011 (SCI-Expanded)

LXXVIII. **Comparing routine neurorehabilitation programme with callisthenic exercises in multiple sclerosis**
KESER İ., MERİÇ A., KIRDI N., Kurne A., KARABUDAK R.
NEUROREHABILITATION, vol.29, no.1, pp.91-98, 2011 (SCI-Expanded)

LXXIX. **A comparative assessment of cerebral white matter by magnetization transfer imaging in early- and adult-onset multiple sclerosis patients matched for disease duration**
Oguz K. K., Kurne A., Aksu A. O., Taskiran A., KARABULUT E., KARABUDAK R.
JOURNAL OF NEUROLOGY, vol.257, no.8, pp.1309-1315, 2010 (SCI-Expanded)

LXXX. **Familial Mediterranean fever and central nervous system involvement: a case series.**
KALYONCU U., Eker A., Oguz K. K., Kurne A., Kalan I., Topcuoglu A. M., Anlar B., BİLGİNER Y., ARICI M., YILMAZ E., et

al.
Medicine, vol.89, no.2, pp.75-84, 2010 (SCI-Expanded)

LXXXI. **Cumulative Corticosteroid Doses and Osteoporosis in Patients with Multiple Sclerosis**
Arslan S., Celiker R., KARABUDAK R.
TURKISH JOURNAL OF RHEUMATOLOGY, vol.25, no.4, pp.191-195, 2010 (SCI-Expanded)

LXXXII. **An unusual central nervous system involvement in rheumatoid arthritis: combination of pachymeningitis and cerebral vasculitis**
Kurne A., KARABUDAK R., KARADAĞ Ö., Yalcin-Cakmakli G., Karli-Oguz K., Yavuz K., Calguneri M., TOPÇUOĞLU M. A.
RHEUMATOLOGY INTERNATIONAL, vol.29, no.11, pp.1349-1353, 2009 (SCI-Expanded)

LXXXIII. **The validity and test-retest reliability of the Leeds Multiple Sclerosis Quality of Life scale in Turkish patients**
Akbiyik D. I., Sumbuloglu V., Guney Z., ARMUTLU K., Korkmaz N., KESER İ., Yuksel M. M., KARABUDAK R.
INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH, vol.32, no.2, pp.162-166, 2009 (SSCI)

LXXXIV. **Interferon-beta Theraphy in Multiple Sclerosis Patients: is Response Age Dependent?**
Kurne A., TERZİ M., Aydin O. F., ONAR M. K., KARABUDAK R.
JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH, vol.26, no.2, pp.131-138, 2009 (SCI-Expanded)

LXXXV. **A clinically isolated syndrome: A challenging entity**
Kurne A., Isikay I. C., Karlioguz K., KALYONCU U., AYDIN Ö. F., Calguneri M., KARABUDAK R.
JOURNAL OF NEUROLOGY, vol.255, no.11, pp.1625-1635, 2008 (SCI-Expanded)

LXXXVI. **Soluble trail and BAFF levels in multiple sclerosis during interferon-beta therapy**
Kurne A., Aydin O. F., Guec D., Sayat G., Canpinar H., Yoeruebulut M., KARABUDAK R.
JOURNAL OF NEUROIMMUNOLOGY, vol.203, no.2, pp.137-138, 2008 (SCI-Expanded)

LXXXVII. **Recurrent alien hand syndrome in a multiple sclerosis case**
Kurne A., Cakmakli G. Y., KARABUDAK R.
NEUROLOGIST, vol.14, no.5, pp.316-317, 2008 (SCI-Expanded)

LXXXVIII. **Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis**
Goodin D. S., Biermann L. D., Bohlega S., Boiko A., Chofflon M., Gebeily S., Gouider R., Havrdova E., Jakab G., Karabudak R., et al.
CURRENT MEDICAL RESEARCH AND OPINION, vol.23, no.11, pp.2823-2832, 2007 (SCI-Expanded)

LXXXIX. **White matter alteration in a patient with Graves' disease**
Kurne A., Aydin O. F., Karabudak R.
JOURNAL OF CHILD NEUROLOGY, vol.22, no.9, pp.1128-1131, 2007 (SCI-Expanded)

XC. **Psychometric study of Turkish version of Fatigue Impact Scale in multiple sclerosis patients**
Armutlu K., Keser I., Koikmaz N., Akbiyik D. I., Sumbuloglu V., Guney Z., Karabudak R.
JOURNAL OF THE NEUROLOGICAL SCIENCES, vol.255, pp.64-68, 2007 (SCI-Expanded)

XCI. **The validity and reliability of the Fatigue Severity Scale in Turkish multiple sclerosis patients**
Armutlu K., Korkmaz N. C., Keser I., Sumbuloglu V., Akbiyik D. I., Guney Z., Karabudak R.
INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH, vol.30, no.1, pp.81-85, 2007 (SSCI)

XCII. **Aphasic status epilepticus with periodic lateralized epileptiform discharges in a bilingual patient as a presenting sign of "AIDS-toxoplasmosis complex"**
OEZKAYA G., Kurne A., Uenal S., Oguz K. K., Karabudak R., Saygi S.
EPILEPSY & BEHAVIOR, vol.9, no.1, pp.193-196, 2006 (SCI-Expanded)

XCIII. **Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients - One year follow-up results**
KARABUDAK R., KURNE A., GUC D., Sengelen M., CANPINAR H., KANSU E.
JOURNAL OF NEUROLOGY, vol.251, no.3, pp.279-283, 2004 (SCI-Expanded)

XCIV. **Multiphasic disseminated encephalomyelitis: A 4-year follow-up**
Ünal I., DOĞULU F. Ç., SAYGI S., FIRAT M., RUACAN Ş., KARABUDAK R.
European Neurology, vol.43, no.1, pp.55-58, 2000 (SCI-Expanded)

XCV. **Familial Mediterranean fever and multiple sclerosis**
TOPÇUOĞLU M. A., KARABUDAK R.
JOURNAL OF NEUROLOGY, vol.244, no.8, pp.510-514, 1997 (SCI-Expanded)

Articles Published in Other Journals

I. **Factors Affecting Bone Mineral Density in Male Patients with Primary Progressive Multiple Sclerosis**
Arican A. C., Kutsal Y. G., Acar N. P., AKBIYIK F., KARAHAN S., KARABUDAK R.
TURK OSTEOPOROZ DERGISI-TURKISH JOURNAL OF OSTEOPOROSIS, vol.26, no.2, pp.115-120, 2020 (ESCI)

II. **The COVID-19 from Neurological Overview**
Acar T., Demirel E. A., AFSAR N., AKÇALI A., Demir G. A., ALAGÖZ A. N., Mengi T. A., ARSAVA E. M., Ayta S., Bebek N., et al.
TURKISH JOURNAL OF NEUROLOGY, vol.26, no.2, pp.58-108, 2020 (ESCI)

III. **Investigation of Adaptation to Successive Postural Perturbations in Patients with Multiple Sclerosis**
SALCI Y., KARANFİL E., AYVAT E., Balkan A. F., KARAKAYA KARABULUT J., AKSOY S., ARMUTLU K., Tuncer A., KARABUDAK R.
TURKISH JOURNAL OF NEUROLOGY, vol.26, no.1, pp.24-29, 2020 (ESCI)

IV. **Analysis of Peripapillary Retinal Nerve Fiber Layer and Macular Volume in Patients with Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, and Healthy Controls Using Spectral Domain Optical Coherence Tomography in a Turkish Cohort**
ÇOLPAK IŞIKAY A. İ., GÜLMEZ SEVİM D., Tuncer A., Diker S., KARABUDAK R., Kadayificilar S., Kansu T.
TURKISH JOURNAL OF NEUROLOGY, vol.25, no.1, pp.26-31, 2019 (ESCI)

V. **Multiple Skleroz Hastalarının Tamamlayıcı ve Alternatif Tedavi Kullanım Durumlarının Belirlenmesi.**
DURU AŞİRET G., Düğer ü., KAPUCU S., TUNCER M. A., KARABUDAK R.
Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi, vol.6, no.3, pp.1-6, 2017 (Peer-Reviewed Journal)

VI. **Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks**
Alroughani R., Altintas A., Al Jumah M., Sahraian M., Alsharoqi I., AlTahan A., Daif A., Dahdaleh M., Deleu D., Fernandez O., et al.
MULTIPLE SCLEROSIS INTERNATIONAL, vol.2016, 2016 (ESCI)

VII. **Case Study Application for C-Support Vector Classification: The Estimation of MS Subgroup Classification with Selected Kernels and Parameters**
Karaca Y., Hayta S., KARABUDAK R.
EUROPEAN JOURNAL OF PURE AND APPLIED MATHEMATICS, vol.9, no.2, pp.196-215, 2016 (ESCI)

VIII. **Linear Modeling of Multiple Sclerosis and Its Subgroubs**
Karaca Y., OSMAN O., KARABUDAK R.
TURKISH JOURNAL OF NEUROLOGY, vol.21, no.1, pp.7-12, 2015 (ESCI)

IX. **Recurrent optic neuritis: clues from a long-term follow up study of recurrent and bilateral optic neuritis patients**
Kurne A., KARABUDAK R., YALÇIN ÇAKMAKLI G., Gursoy-Ozdemir Y., Aydin P., Ilksen-Colpak A., LÜLE S., Kansu T.
EYE AND BRAIN, vol.2, pp.15-20, 2010 (ESCI)

X. **The Effect of Walking Distance on EDSS Score in Patients with Multiple Sclerosis**
Tombak K. B., ARMUTLU K., KARABUDAK R.
TURKISH JOURNAL OF NEUROLOGY, vol.16, no.2, pp.72-77, 2010 (ESCI)

XI. **Use of Mitoxantrone in Early Secondary Progressive Multiple Sclerosis: An Observational Study of 48 Patients with Clinical and MRI Outcomes**
Kilic A. K., Kurne A., BAŞTAN B., Cikrikci I., Bas D. F., Bulus M., Eker N., Kislak G., Bulut E., Oguz K. K., et al.
TURKISH JOURNAL OF NEUROLOGY, vol.15, no.2, pp.64-70, 2009 (ESCI)

XII. **Evaluating the Existence of Other Autoimmune Diseases Among Multiple Sclerosis Patients and Their First Degree Relatives**

Kurne A., Terzi M., Erturk O., Onar M., Dogan B. G., KARABUDAK R.
TURKISH JOURNAL OF NEUROLOGY, vol.14, no.2, pp.104-109, 2008 (ESCI)

XIII. **The colorful clinical spectrum of cerebral toxoplasmosis in five HIV positive cases: What comes out of Pandora's box? HIV pozitif beş olguda serebral toksoplazmozisin renkli klinigi: Pandora'nın kutusundan çıkanlar**
Kurne A., Özkaya G., Karlioğuz K., Shorbagi A., Ustaçelebi Ş., KARABUDAK R., ÜNAL S.
Mikrobiyoloji Bulteni, vol.40, no.1-2, pp.85-92, 2006 (Scopus)

XIV. **Steps in the Pathogenesis of Multiple Sclerosis - I: From Neuroinflammation to Neurodegeneration**
Kurne A., KARABUDAK R., AYDIN Ö. F.
TURKISH JOURNAL OF NEUROLOGY, vol.12, no.1, pp.5-13, 2006 (ESCI)

XV. **Steps in Multiple Sclerosis Pathogenesis - II: The Role of Biological Markers, Sodium Channels and Glutamate in Neurodegeneration**
AYDIN Ö. F., Kurne A., KARABUDAK R.
TURKISH JOURNAL OF NEUROLOGY, vol.12, no.2, pp.98-105, 2006 (ESCI)

Refereed Congress / Symposium Publications in Proceedings

I. **Real World Ocrelizumab Experience of a Tertiary Center in Turkey**
ARSLAN D., Acar-Ozen N. P., KARABUDAK R., Tuncer A.
Virtual Annual Meeting of the American-Academy-of-Neurology, ELECTR NETWORK, 17 - 22 April 2021, vol.96

II. **DİNAMİK KONTRAST MR PERMEABİLİTE GÖRÜNTÜLEMENİN NÖROMYELİTİS OPTİKA SPEKTRUM HASTALARINDA AQUAPORİN KANAL DİSFONKSİYONUNUN GÖSTERİLMESİNDE YERİ OLABİLİR Mİ ?**
OKAR S. V., GÖÇMEN R., PARLAK Ş., ERDENER Ş. E., KARLI OĞUZ H. K., KARABUDAK R., TUNCER M. A.
55. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 15 - 21 November 2019

III. **HEMORAJİK LONGİTUDİNAL EKSTENSİF TRANSVERS MİYELİT: 4 OLGU**
YILMAZ E., GÖÇMEN R., KARABUDAK R., KARLI OĞUZ H. K., TUNCER M. A.
55. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 15 - 21 November 2019

IV. **Dinamik Kontrast MR Permeabilite Görüntülemenin Nöromyelitis Optika Spektrum Hastalarında Aquaporin Kanal Disfonksiyonunun Gösterilmesinde Yeri Olabili rmi**
Okar S., GÖÇMEN R., PARLAK Ş., ERDENER Ş. E., KARLI OĞUZ H. K., KARABUDAK R., TUNCER M. A.
55. Ulusal Nöroloji Kongresi, Turkey, 15 - 21 November 2019

V. **Transcriptomic and immunophenotypic analyses on natural killer cells in RRMS patients under fingolimod therapy**
Acar-Ozen N. P., TUNCER A., Ozkazanc D., Ozbay F. G., KARAOSMANOĞLU B., Goksen S., Taskiran E., ESENDAĞLI G., KARABUDAK R.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.664-665

VI. **BK virus can be neurotropic: a rare cause of PML**
AYVACIOĞLU C., KARABUDAK R., TUNCER A., ÖGE D. D., ELİBOL B., Tan E., GÖÇMEN R., Inkaya C.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.836

VII. **Radyolojik İzole Sendromlu Bireylerde Temporal Peripapiller Retinal Sinir Lifi Tabakası Kalınlığının Azalması ve Beyin Hacim Kaybı ile İlişkisi**
VURAL A., Okar S., TUNCER M. A., Sayat G., Acar N. P., KARABULUT E., KARLI OĞUZ H. K., KADAYIFÇILAR S., KARABUDAK R.
54. Ulusal Nöroloji Kongresi, Antalya, Turkey, 30 November - 06 December 2018

VIII. **ANN Classification of MS Subgroups with Diffusion Limited Aggregation**
Karaca Y., Cattani C., KARABUDAK R.
18th International Conference on Computational Science and Its Applications (ICCSA), Melbourne, Australia, 2 - 05 July 2018, vol.10961, pp.121-136

IX. **Can MR Permeabiltiy and Contast Enhanced (CE)-FLAIR demonstrate AQP4 Channel Dysfuncton NMOSD Patents?: Work in Progress**
OKAR S. V., GÖÇMEN R., TUNCER M. A., KARLI OĞUZ H. K., ERDENER Ş. E., KARABUDAK R.
MS Paris 2017 7th Joint ECTRIMS-ACTRIMS Meeting, Paris, France, 25 - 28 October 2017

X. **Can MR permeability and contast enhanced (CE)-FLAIR demonstrate AQP4 channel dysfunction in NMOSD patients? Work in progress**
OKAR S. V., GÖÇMEN R., KARLI-OGUZ K., TUNCER M., Erdener S. E., KARABUDAK R.
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.819-820

XI. **Spectrum of autoantibodies against myelin oligodendrocyte glycoprotein**
VURAL A., TUNCER M. A., M SPADARO M., KONUŞKAN B., GÖÇMEN R., ANLAR F. B., M REİNDL M., KARABUDAK R., MEINL E.
3rd Congress of the European Academy of Neurology, Amsterdam, Netherlands, 24 - 27 June 2017, vol.24, pp.19-122

XII. **The Maculo-Papillary Bundle and Inner Ganglion Cell Layer Are Affected More Prominently in Radiologically Isolated Syndrome**
KARABUDAK R., Vural A., Acar N. P., TUNCER M. A., Sayat G., KADAYIFÇILAR S.
9th Congress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Bangkok, Thailand, 27 - 29 October 2016, vol.23, pp.326

XIII. **The effect of fingolimod treatment on natural killer cells**
Acar N. P., KARABUDAK R., Ozkazanc D., Sayat-Gurel G., ESENDAĞLI G., TUNCER A.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.176-177

XIV. **Leptomeningeal contrast enhancement in patients with neuromyelitis optica disorder**
OKAR S. V., TUNCER M. A., GÖÇMEN R., ÇOLPAK IŞIKAY A. İ., yılmaz e., KARABUDAK R.
32ND CoNgressof the europeaN Committeefor treatmeNt aND researChiN multiple sClerosis, Londrina, Brazil, 14 June - 17 September 2016

XV. **Factors Affecting Bone Mineral Density Among Male Primary Progressive Multiple Sclerosis Patients**
ÇALIŞKAN A., KUTSAL F. Y., ACAR P., KARABUDAK R., AKBIYIK F., KARAHAN S.
WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Malaga, Spain, 14 - 17 April 2016, vol.27

XVI. **Disease activity in Primary Progressive Multiple Sclerosis**
Vural A., Kurne A. T., Sayat G., Derle E., KARABUDAK R.
ACTRIMS Forum, Louisiana, United States Of America, 18 - 20 February 2016, vol.22, pp.30

XVII. **Rituximab experience in neuromyelitis optica: data from a single center in Turkey**
ERDENER Ş. E., DIKER S., KARABUDAK R., KURNE A. T.
Joint Congress of European Neurology, İstanbul, Turkey, 31 May - 03 June 2014, vol.21, pp.454

XVIII. **Formyl-methionyl-leucyl-phenylalanine (fMLP) peptide as an adjuvant in experimental autoimmune encephalomyelitis (EAE): modulation of neutrophil granulocytes**
KILIÇ A., Tuncer-Kurne A., ESENDAĞLI G., Sayat G., TALİM B., KARABUDAK R.
29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Denmark, 2 - 05 October 2013, vol.19, pp.136

XIX. **Inflammatory pan-demyelination syndrome IPANDS of the whole nervous system**
Vural A., GÜLER E., GÖÇMEN R., TUNCER M. A., KARLI OĞUZ H. K., TEMUÇİN Ç. M., TAN M. E., KARABUDAK R., ERDEM ÖZDAMAR S.
2013 Meeting of the Peripheral Nerve Society, France, 29 June - 03 July 2013, vol.18, pp.1-131

XX. **Evaluation of Th17-related parameters in multiple sclerosis patients under immunomodulatory IFN-beta 1 therapy**
Sayat G., Kurne A., ESENDAĞLI G., Guc D., KARABUDAK R.
11th International Congress of Neuroimmunology (ISNI), Massachusetts, United States Of America, 4 - 08

November 2012, vol.253, pp.77-78

XXI. **Walking and Expanded Disability Status Scale: are self-estimated walking distances accurate?**
Armuthu K., Balci K., FİL BALKAN A., KARABUDAK R.
13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis, Montreal, Canada, 17 - 20 September 2008, vol.14

XXII. **The effects of high-voltage pulsed galvanic stimulation on fatigue in multiple sclerosis patients**
KORKMAZ N. Ç., ARMUTLU K., KESER İ., KIRDI N., KARABUDAK R.
13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis, Montreal, Canada, 17 - 20 September 2008, vol.14

XXIII. **TRAIL and BAFF serial serum levels during interferon beta therapy in MS patients**
Kurne A., CANPINAR H., Aydin O. F., Sayat G., Yoeruebulut M., Guec D., KARABUDAK R.
13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis, Montreal, Canada, 17 - 20 September 2008, vol.14

XXIV. **Clinical and prognostic features of bilateral and unilateral recurrent optic neuritis**
TUNCER M. A., YALÇIN ÇAKMAKLI G., KARABUDAK R., Aydın P., Kansu T.
8th European Neuro-opthalmology Society (EUNOS) Meeting, İstanbul, Turkey, 26 - 29 May 2007, vol.31

XXV. **Operküler sendrom ile kendini gösteren santral sinir sistemi vasküliti**
YALÇIN ÇAKMAKLI G., GÜREL Ş. C., ÇOLPAK IŞIKAY A. İ., SAYGI S., KARABUDAK R., SÖYLEMEZOĞLU A. F., NURLU G.
42. Ulusal Nöroloji Kongresi, Antalya, Turkey, 12 - 17 November 2006, vol.12, pp.103-104

XXVI. **Yabancı el sendromunun farklı yüzleri**
YALÇIN ÇAKMAKLI G., YILDIZ SARIKAYA F. G., BAŞ D. F., TUNCER M. A., TOPÇUOĞLU M. A., KARABUDAK R., ELİBOL B., SAKA TOPÇUOĞLU E.
42. Ulusal Nöroloji Kongresi, Antalya, Turkey, 12 November 2002 - 17 November 2006, vol.12, pp.77-78

XXVII. **The role of sodium in predicting HIV related neurological complications**
Kurne A., Sahin G. O., Karlioguz K., Sahin S. U., Karabudak R.
8th International Conference of Neuroimmunology, Nagoya, Japan, 15 - 19 October 2006, vol.178, pp.259-260

XXVIII. **Type I diabetes mellitus and central nervous system demyelinization: A possible association**
Kurne A., Basak E. S., Karabudak R.
8th International Conference of Neuroimmunology, Nagoya, Japan, 15 - 19 October 2006, vol.178, pp.264

Supported Projects

TUNCER M. A., ACAR N. P., ESENDAĞLI G., SAYAT-GÜREL G., KARABUDAK R., Project Supported by Higher Education Institutions, Multiple Skleroz Hastalarında CCRL2 Atipik Kemokin Reseptör Polimorfizminin Kemokin Düzeyleri ve Hastalık Süreci ile İlişkisi, 2015 - 2019

KUTSAL F. Y., ÇALIŞKAN A., KARABUDAK R., AKBIYIK F., ACAR N. P., KARAHAN S., Project Supported by Higher Education Institutions, Erkek primer progresif multiple skleroz(MS) olgularında kemik mineral yoğunluğu (KMD) ile etkileşen faktörler, 2015 - 2016

Metrics

Publication: 138
Citation (WoS): 540
Citation (Scopus): 391
H-Index (WoS): 12
H-Index (Scopus): 12